Follow-up at 1 year and beyond of women with gestational diabetes treated with insulin and/or oral glucose-lowering agents: a core outcome set using a Delphi survey
Bogdanet, Delia; Reddin, Catriona; Macken, Esther; Griffin, Tomas P.; Fhelelboom, Narjes; Biesty, Linda; Thangaratinam, Shakila; Dempsey, Eugene M.; Crowther, Caroline; Galjaard, Sander; Maresh, Michael; Loeken, Mary R.; Napoli, Angela; Anastasiou, Eleni; Noctor, Eoin; de Valk, Harold W.; van Poppel, Mireille N. M.; Agostini, Andrea; Clarson, Cheril; Egan, Aoife M.; O'Shea, Paula M.; Devane, Declan; Dunne, Fidelma P.
Date:
2019-07-04
Copyright:
© The Author(s) 2019. This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.
Citation:
Bogdanet, D., Reddin, C., Macken, E., Griffin, T.P., Fhelelboom, N., Biesty, L., Thangaratinam, S., Dempsey, E., Crowther, C., Galjaard, S. and Maresh, M. (2019) 'Follow-up at 1 year and beyond of women with gestational diabetes treated with insulin and/or oral glucose-lowering agents: a core outcome set using a Delphi survey'. Diabetologia, 62(11), pp. 2007-2016. doi:10.1007/s00125-019-4935-9
Abstract:
Gestational diabetes mellitus (GDM) is linked with a higher lifetime risk for the development of impaired fasting glucose, impaired glucose tolerance, type 2 diabetes, the metabolic syndrome, cardiovascular disease, postpartum depression and tumours. Despite this, there is no consistency in the long-term follow-up of women with a previous diagnosis of GDM. Further, the outcomes selected and reported in the research involving this population are heterogeneous and lack standardisation. This amplifies the risk of reporting bias and diminishes the likelihood of significant comparisons between studies. The aim of this study is to develop a core outcome set (COS) for RCTs and other studies evaluating the long-term follow-up at 1 year and beyond of women with previous GDM treated with insulin and/oral glucose-lowering agents.
Show full item record
Except where otherwise noted, this item's license is described as © The Author(s) 2019. This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.